Evidence map›Paper›PMID 21518756›Full record

ArticleThe Journal of biological chemistry2011

Dynamic interdomain interactions contribute to the inhibition of matrix metalloproteinases by tissue inhibitors of metalloproteinases.

Albert G Remacle, Sergey A Shiryaev, Ilian A Radichev, Dmitri V Rozanov, Boguslaw Stec, Alex Y Strongin

Open access · hybridAbstract read
In one paragraph

Article in The Journal of biological chemistry, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.0field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 16 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Review
  7. Article
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Albert G RemacleCancer Research Center, Sanford-Burnham Medical Research Institute, La Jolla, California 92037, USA.
Sergey A Shiryaev
Ilian A Radichev
Dmitri V Rozanov
Boguslaw Stec
Alex Y Strongin
Sanford Burnham Prebys Medical Discovery Institute · USDiscovery Institute · US

Funding

METALLOPROTEINASES IN TUMOR NEOVASCULARIZATIONR01CA083017 · NCI · SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE · PI STRONGIN, ALEX Y · 1999 to 2014
$3.8M
MT1-MMP pericellular proteolysis in malignancyR01CA077470 · NCI · SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE · PI STRONGIN, ALEX Y · 1999 to 2009
$3.1M
NCI NIH HHS CA77470NCI NIH HHS CA83017NCI NIH HHS R01 CA077470NCI NIH HHS R01 CA083017
6 · The paper itself

Abstract

Because of their important function, matrix metalloproteinases (MMPs) are promising drug targets in multiple diseases, including malignancies. The structure of MMPs includes a catalytic domain, a hinge, and a hemopexin domain (PEX), which are followed by a transmembrane and cytoplasmic tail domains or by a glycosylphosphatidylinositol linker in membrane-type MMPs (MT-MMPs). TIMPs-1, -2, -3, and -4 are potent natural regulators of the MMP activity. These are the inhibitory N-terminal and the non-inhibitory C-terminal structural domains in TIMPs. Based on our structural modeling, we hypothesized that steric clashes exist between the non-inhibitory C-terminal domain of TIMPs and the PEX of MMPs. Conversely, a certain mobility of the PEX relative to the catalytic domain is required to avoid these obstacles. Because of its exceedingly poor association constant and, in contrast with TIMP-2, TIMP-1 is inefficient against MT1-MMP. We specifically selected an MT1-MMP·TIMP-1 pair to test our hypothesis, because any improvement of the inhibitory potency would be readily recorded. We characterized the domain-swapped MT1-MMP chimeras in which the PEX of MMP-2 (that forms a complex with TIMP-2) and of MMP-9 (that forms a complex with TIMP-1) replaced the original PEX in the MT1-MMP structure. In contrast with the wild-type MT1-MMP, the diverse proteolytic activities of the swapped-PEX chimeras were then inhibited by both TIMP-1 and TIMP-2. Overall, our studies suggest that the structural parameters of both domains of TIMPs have to be taken into account for their re-engineering to harness the therapeutic in vivo potential of the novel TIMP-based MMP antagonists with constrained selectivity.

Indexed as

Matrix Metalloproteinase InhibitorsModels, MolecularAnimalsCHO CellsCollagenasesCricetinaeCricetulusHumansMiceProtein Structure, QuaternaryProtein Structure, TertiaryRecombinant Fusion ProteinsTissue Inhibitor of MetalloproteinasesCollagenasesMatrix Metalloproteinase InhibitorsRecombinant Fusion ProteinsTissue Inhibitor of Metalloproteinases

Identifiers

PMID21518756
PMCPMC3121501
OpenAlexW2048469845

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.